From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 14:50:15 +0000

To: 9)
Subject: FW: Developing Immunity to SARS-CoV-2 and Ivlig

  

Please respond to this person.

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

    

 

Phone:—f  ()
FAX: (301) 496-4409
E-mail{ = D) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

 

From: Dr. Art Kamm <art@kammconsultinginc.com>
Sent: Friday, March 6, 2020 7:47 AM

To: Fauci, Anthony (NIH/NIAID) [E] ©) G>; Lane, Cliff (NIH/NIAID) [E]
CO >

Subject: Developing Immunity to SARS-CoV-2 and Ivig
Dear Dr. Fauci and Dr. Lane:

| have been following the growing international outbreak of COVID-19 and wanted to share a thought with
you, understanding that this may have already been thought of. My early academic research (reference
provided, PNAS) involved cancer immunology where it contributed to a growing body of information that
certain tumor cells could possess unique surface antigens that could be used for immunologic therapy
(https://www.pnas.org/content/pnas/75/12/5912.full.pdf). My career then took me to executive and senior
executive/corporate officer positions in publicly-held pharmaceutical corporations (Glaxo and Salix,
respectively) overseeing R&D of therapeutic agents. My experience has included both pharmaceuticals and
biologics.

 

Our current understanding of COVID-19 mortality is that it appears to be concentrated in the elderly and
those with underlying medical conditions. In healthy individuals (although still early) it appears that many of

NIH-000911
